CytomX Therapeutics Inc CTMX:NASDAQ

Last Price$1.62NASDAQ Closing Price as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.07(4.14%)
Bid (Size)$1.62 (192)
Ask (Size)$1.63 (57)
Day Low / High$1.56 - 1.74
Volume648.4 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/20/2022


CytomX Therapeutics Inc ( NASDAQ )

Price: $1.62
Change: -0.07 (4.14%)
Volume: 648.4 K
4:00PM ET 5/20/2022

Otonomy Inc ( NASDAQ )

Price: $1.84
Change: -0.10 (5.15%)
Volume: 45.1 K
4:00PM ET 5/20/2022

RVL Pharmaceuticals PLC ( NASDAQ )

Price: $1.38
Change: 0.00 (0.00%)
Volume: 34.9 K
4:00PM ET 5/20/2022

Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $1.93
Change: +0.03 (1.58%)
Volume: 270.4 K
4:00PM ET 5/20/2022

MediciNova Inc ( NASDAQ )

Price: $2.39
Change: -0.01 (0.42%)
Volume: 29.0 K
4:00PM ET 5/20/2022

Read more news Recent News

--Wedbush Adjusts Price Target for CytomX Therapeutics to $6 From $10, Maintains Outperform Rating
2:56PM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q1 Revenue $17.1M, vs. Street Est of $21.2M
4:21PM ET 5/05/2022 MT Newswires


CytomX Therapeutics' 2021 Loss Widens, Revenue Declines
5:28PM ET 3/01/2022 MT Newswires

CytomX Therapeutics (CTMX) said Tuesday its 2021 net loss widened to $1.30 per share from $0.71 per share a year earlier. Analysts polled by Capital IQ...

-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q4 Revenue $69.6M, vs. Street Est of $25.6M
4:22PM ET 3/01/2022 MT Newswires


Company Profile

Business DescriptionCytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. View company web site for more details
Address151 Oyster Point Boulevard
South San Francisco, California 94080-1913
Number of Employees137
Recent SEC Filing05/11/20224
Chairman, President & Chief Executive OfficerSean A. McCarthy
Chief Financial Officer & Senior Vice PresidentCarlos E. Campoy
Senior Vice President & Head-ResearchMarcia P. Belvin
Chief Medical Officer & Senior Vice PresidentAlison L. Hannah

Company Highlights

Price Open$1.70
Previous Close$1.69
52 Week Range$1.51 - 8.63
Market Capitalization$105.9 M
Shares Outstanding65.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.41
Beta vs. S&P 500N/A
Revenue$59.5 M
Net Profit Margin-129.97%
Return on Equity-91.89%

Analyst Ratings as of 02/02/2022

Consensus RecommendationConsensus Icon
Powered by Factset